TUDCA: What the Clinical Studies Actually Show

Tauroursodeoxycholic acid, better known as TUDCA, has moved from hepatology textbooks into gym bags. Online it is described as a liver shield, a metabolic booster and even a neuroprotective agent. Our editorial team went back to the primary research to separate what has been tested in people from what has only been seen in cell cultures and mice.

What TUDCA is and where it comes from

TUDCA is a bile acid. More precisely, it is ursodeoxycholic acid (UDCA) conjugated with the amino acid taurine. Small amounts occur naturally in human bile, and much larger amounts are found in the bile of bears, which is why it featured in traditional Chinese medicine for centuries. The material sold today is produced synthetically or semi-synthetically, so no animal sourcing is required.

Its close relative UDCA is a licensed, prescription-only medicine in the UK, used chiefly for primary biliary cholangitis and for dissolving certain cholesterol gallstones. TUDCA itself is sold here as a food supplement, while in some European countries, such as Italy, it has historically been available as a medicinal product. That regulatory split matters: a medicine has had its quality, efficacy and safety assessed, whereas a supplement has not.

Bile acids are not just detergents for fat digestion. They act as signalling molecules, binding receptors such as FXR and TGR5, and they influence cholesterol handling, inflammation and cell survival. TUDCA in particular has attracted interest as a so-called chemical chaperone, a molecule that helps cells cope with misfolded proteins in the endoplasmic reticulum.

That last property is the basis for most of the excitement. Endoplasmic reticulum stress is implicated in obesity, type 2 diabetes, fatty liver and neurodegeneration, so a compound that eases it sounds like a universal fix. The key question is how much of this survives the move from laboratory to clinic.

Liver disease: the strongest evidence base

The most robust human data come from cholestatic liver disease, where bile flow is impaired. Much of that evidence actually concerns UDCA rather than TUDCA. Large randomised trials, including the multicentre study by Poupon and colleagues published in 1991, showed that UDCA improves liver biochemistry in primary biliary cholangitis, and it remains first-line therapy in current European guidelines.

TUDCA has been compared with UDCA in smaller trials in the same condition, generally showing similar effects on liver enzymes and good tolerance. Because TUDCA is partly converted to UDCA in the gut and vice versa, researchers consider the two broadly comparable, although TUDCA is more water-soluble and may be absorbed slightly differently.

What these studies do not show is that TUDCA protects a healthy liver from alcohol, medication or other hepatotoxic substances. Improved enzymes in a person with diagnosed cholestasis are a different matter from preventing injury in someone without liver disease. This distinction is often lost in marketing copy.

Clinicians also stress that normalising a blood test is not the same as improving long-term outcomes. Even for UDCA, where decades of data exist, benefit depends heavily on the specific diagnosis, and some conditions, such as primary sclerosing cholangitis, have not responded well to high doses.

Metabolism and insulin sensitivity

A frequently cited mouse study by Ozcan and colleagues in Science (2006) showed that chemical chaperones, including TUDCA, reduced endoplasmic reticulum stress and restored glucose control in obese, diabetic mice. That paper triggered a wave of interest in TUDCA as a metabolic agent.

The human follow-up is limited but informative. In a randomised, placebo-controlled trial published in Diabetes in 2010, Kars and colleagues gave obese, insulin-resistant adults 1,750 mg of TUDCA daily for four weeks. Insulin sensitivity in the liver and muscle improved by around 30 per cent, whereas adipose tissue showed no change.

The trial was small, short and carried out under close supervision, so it cannot tell us whether the effect persists, whether it translates into lower diabetes risk, or whether it applies to lean, active people. It also used a fairly high daily amount, well above what many commercial capsules provide per serving.

For athletes, the honest summary is that TUDCA has shown a metabolic signal in a clinical population, but there are no trials demonstrating improved body composition, recovery or performance in trained people.

Neurological research: a cautionary tale

TUDCA has been studied in amyotrophic lateral sclerosis (ALS), a fatal motor neurone disease. A small Italian trial by Elia and colleagues (2016) suggested slower functional decline in patients taking TUDCA alongside riluzole. That encouraged larger programmes.

A combination of sodium phenylbutyrate and taurursodiol was then tested in the CENTAUR trial, published in the New England Journal of Medicine in 2020, which reported a modest slowing of decline. The product received conditional approval in some markets. However, the larger confirmatory PHOENIX trial did not show a benefit, and the manufacturer withdrew the product in 2024.

This sequence is a useful reminder for anyone reading supplement claims: early, small positive studies are common, and they frequently fail to replicate. Animal research in retinal degeneration, Parkinson's disease and stroke remains interesting but has not yet produced proven human treatments.

From a practical standpoint, none of this neurological research supports taking TUDCA for brain health or cognition in healthy people.

Practical points for UK readers

If you are considering TUDCA, a few practical observations are worth keeping in mind:

• Quality is not guaranteed. Supplements are not batch-tested by the MHRA, so look for independent third-party testing.
• Amounts vary widely. Clinical studies used roughly 750–1,750 mg per day under supervision; label amounts often differ.
• Abnormal liver tests need a diagnosis, not a supplement. See your GP before self-treating.
• Gastrointestinal upset, especially loose stools, is the most commonly reported side effect.
• Pregnancy, breastfeeding and gallbladder disease call for medical advice before use.

Athletes in tested sport should note that TUDCA is not on the WADA Prohibited List, but any supplement carries a contamination risk, which is why schemes such as Informed Sport exist.

Conclusions of the editorial team

TUDCA is a genuinely interesting molecule with a respectable pedigree in hepatology, but most of its reputation in sports circles is built on extrapolation. The best data concern people with diagnosed cholestatic liver disease, and much of that evidence belongs to its licensed cousin UDCA.

One small trial suggests improved insulin sensitivity in obese adults, and neurological research has had a rollercoaster history ending in a failed confirmatory trial. Claims of liver protection for healthy gym-goers remain untested.

If you would like to read further, we suggest our articles on TUDCA side effects and contraindications, on interpreting liver function tests, and on how bile acids influence fat metabolism.

References

1. Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324(22):1548–1554.
2. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137–1140.
3. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899–1905.
4. Elia AE, Lalli S, Monsurrò MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45–52.
5. Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930.
6. Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3(3):58–69.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172.